Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polybactum is a vaginal mucoadhesive medical device (Class IIa) developed by Effik International. It is formulated as vaginal ovules containing polycarbophil, a bioadhesive agent, and lauryl glucoside, a nonionic surfactant. The product works by forming a protective film on the vaginal wall that acts as a mechanical barrier against pathogen colonization, specifically *Gardnerella vaginalis*. It exerts a selective bacteriostatic action that inhibits *G. vaginalis* while preserving normal physiological vaginal flora and helps acidify the vaginal pH to promote the growth of lactobacilli. Polybactum is indicated for reducing vaginal infections and preventing the recurrence of bacterial vaginosis, and it is marketed as an approved medical device in Europe.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Polybactum.